title: Tumor vasculature is a key determinant for the efficiency of nanoparticle-mediated siRNA delivery.
abstract: Delivering small interfering RNA (siRNA) to tumors using clinically viable formulations remains the primary technical hurdle that prevents the development of siRNA therapy for cancer treatment. Over the past several years, significant effort has been devoted to explore novel delivery strategies, whereas relatively little attention has been paid to understand the impact of physiological constrains such as tumor vasculature on the efficiency of siRNA delivery. Using the previously described positive-readout tumor models where successful siRNA delivery leads to an upregulation of β-galactosidase within tumor sections, we analyzed the spatial distribution of localized target knockdown within tumor sections relative to tumor hypoxia and found that stable nucleic acid lipid particle (SNALP), a lipid nanoparticle-based delivery system, predominantly delivers siRNA to areas adjacent to functional tumor blood vessels. Increasing tumor vascularity by ectopic expression of VEGF resulted in more efficient siRNA delivery to tumors using SNALP. SNALP-mediated delivery of a siRNA-targeting Ran GTPase led to target knockdown and significant antitumor efficacy in the highly vascularized HepG2-derived liver tumors, but not in the poorly vascularized HCT-116-derived liver tumors. These results highlight the significant impact of tumor vasculature on siRNA delivery and call for a more focused effort on addressing tumor penetration after extravasation, an area of only limited attention currently.
authors.affiliation: siRNA Therapeutics, Cancer Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL, USA.
authors.forename: L
authors.initials: L
authors.lastname: Li
authors.forename: R
authors.initials: R
authors.lastname: Wang
authors.forename: D
authors.initials: D
authors.lastname: Wilcox
authors.forename: X
authors.initials: X
authors.lastname: Zhao
authors.forename: J
authors.initials: J
authors.lastname: Song
authors.forename: X
authors.initials: X
authors.lastname: Lin
authors.forename: W M
authors.initials: WM
authors.lastname: Kohlbrenner
authors.forename: S W
authors.initials: SW
authors.lastname: Fesik
authors.forename: Y
authors.initials: Y
authors.lastname: Shen
mesh_terms: D000818:Animals; D015687:Cell Hypoxia; D045744:Cell Line, Tumor; D005260:Female; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D008113:Liver Neoplasms / Q000098:blood supply* / Q000628:therapy*; D051379:Mice; D016513:Mice, SCID; D053758:Nanoparticles; D034741:RNA, Small Interfering / Q000008:administration & dosage*; D042461:Vascular Endothelial Growth Factor A / Q000494:pharmacology; D001616:beta-Galactosidase / Q000378:metabolism
chemical_list: D034741:RNA, Small Interfering; D042461:Vascular Endothelial Growth Factor A; D001616:beta-Galactosidase